Therefore, the aim of the present study was to calculate the cumulative lifetime risks for CRC and EC in Lynch syndrome using a cohort of proven MLH1, MSH2 and MSH6 mutation carriers. This evidence concerns the gene MLH1 and colorectal carcinoma.